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Objective. The aim was to evaluate immunoexpression of matrix metalloproteinases (MMPs) 1, 2, 7, 9, and 26 in
calcifying cystic odontogenic tumor (CCOT).
Study design. Ten cases of CCOT were assessed by immunohistochemical expression of MMPs 1, 2, 7, 9, and 26 in the
parenchyma and stroma. Metalloproteinase immunoexpressions and their distribution pattern were semiquantitatively scored.
Results. MMPs were expressed in the parenchyma and stroma in all cases of CCOT. Regarding the percentage of
immunostained parenchymal cells, MMPs 1, 7, and 9 showed score 2 in 100% of cases. For MMP-2, there was a
predominance of score 0 (90%), whereas for MMP-26 immunostaining was varied.
Conclusions. The staining of these metalloproteinases, with the exception of MMP-2, suggests their contribution to
tumor growth and expansion. The presence of these metalloproteinases in stromal cells reveals the active participation
of these cells in the degradation of the extracellular matrix, contributing to the growth of the tumor studied. (Oral Surg
Oral Med Oral Pathol Oral Radiol Endod 2011;112:609-615)The calcifying odontogenic cyst was first described by
Gorlin in 1962 as a distinct pathologic entity, named a
non-neoplastic cystic lesion. However, Praetorius et al. in
1981 proposed a new classification and reviewed the
neoplastic potential of this process. In the current 2005
World Health Organization (WHO) classification, the cal-
cifying odontogenic cyst is defined as a benign cystic
neoplasm derived from odontogenic epithelium, with the
participation of ectomesenchyma that may or may not
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doi:10.1016/j.tripleo.2011.06.009have hard tissue formation and is renamed calcifying
cystic odontogenic tumor (CCOT).1-4
The CCOT constitutes 1% of odontogenic lesions and
may be intra- or extraosseous. The maxilla and mandible
are affected in the same proportion, more commonly in
the anterior region.1,5,6 Histopathologically, it is charac-
terized by the proliferation of ameloblastomatous epithe-
lium consisting of cubic or columnar cells in the basal
layer similar to ameloblasts. In the shallower portions,
cells are loosely arranged, remnants of the stellate reticu-
lum of the enamel. Ghost cells are evident in varying
amount, and some may be calcified. The presence of
dysplastic dentin and proliferation of odontogenic epithe-
lium may be observed adjacent to the tissue.4,5
Matrix metalloproteinases (MMPs) comprise a family
of calcium- and zinc-dependent endopeptidases that are
capable of degrading components of extracellular matrix
(ECM) and basal layer, participating in physiologic events
and pathologic processes and facilitating tumor growth,
invasion, and metastasis.7-9
To date, 24 types of MMPs have been identified, and
their classification is based on the specific substrate that
they degrade and their molecular structure. MMPs are
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610 Ribeiro et al. November 2011divided into -soluble MMPs and membrane-associated
MMPs. Among the soluble MMPs are the collagenases
(MMP-1, -8, and -13), gelatinases (MMP-2 and -9),
stromelysins (MMP-3 and -10), matrilysins (MMP-7 and
-26) and a heterogeneous group of MMPs (MMP-12, -19,
-20, -21, -23, -27, and -28). MMPs associated with the
membrane are represented by the MMPs 14, 15, 16, 17,
24, and 25.7,10,11
MMP-1 is a type of collagenase that has the ability to
degrade collagen types I, II, III, VII, VIII, and X and other
molecules.12,13 Degradation of fibrillar collagen leads to
the formation of molecules that are thermally unstable and
form gels that are subsequently degraded by gelatinases,
represented by the MMP-2 and -9.12 MMP-7 and -26, the
matrilysins, are involved in cell proliferation, apoptosis,
cell invasion, and metastasis.14
To better understand the interaction between tumor
cells and extracellular matrix in CCOT, the present
study aimed to evaluate and compare the immunohis-
tochemical expression of MMPs 1, 2, 7, 9, and 26 in
calcifying cystic odontogenic tumors.
MATERIALS AND METHODS
The research was approved by the Ethics Committee of
the Federal University of Rio Grande do Norte. Ten cases
of calcifying cystic odontogenic tumor were obtained
from the files of the Pathology Laboratory of the Depart-
ment of Oral Pathology, Federal University of Rio Grande
do Norte. The diagnosis was confirmed by the authors
through the review of slides stained with hematoxylin and
eosin, following the WHO classification (2005). Of the 10
cases, 2 were associated with odontoma and 1 showed is-
lands of odontogenic epithelium similar to ameloblastoma.
Immunohistochemical method
The material selected had previously been fixed in 10%
formalin and embedded in paraffin; 3 m thickness that
were extended on glass slides containing the adhesive
3-amino-propiltrietoxi-silane (Sigma Chemical Co., St.
Louis, MO, USA). Sections were subjected to deparaf-
finization in xylene through 2 baths, the first being 60°C
for 30 minutes and the second at room temperature for 20
minutes. The sections were rehydrated in a sequence of
Table I. Applied monoclonal antibodies and stained c
Clone Specification Source
41-1E5 MMP-1 Calbiochem
17B11 MMP-2 NovoCastra
2C3 MMP-9 Novocastra
Ab-1/ID2 MMP-7 Labvision/Neomarkers
AHP756 MMP-26 Serotecalcohol to water and washed in 2 passages of distilledwater for 5 minutes each chromogenic blocking of endog-
enous peroxidase was done using hydrogen peroxide (10
volumes). Subsequently, the sections were washed in wa-
ter twice and immersed in a buffered solution of Tris
(hydroxymethyl) aminomethane (Tris-HCl), pH 7.4, for 5
minutes each. The incubation of sections was performed
with antibodies diluted in buffered Tris-HCl solution (Ta-
ble I) with streptavidin-biotin complex (LSAB System-
HRP; Dakocytomation, Glostrup, Denmark) for 30 min-
utes at room temperature. Peroxidase activity was
visualized by immersing tissue sections in diaminobenzi-
dine (D5637; Sigma Chemical, St. Louis, MO), resulting
in a brown reaction product. For counterstaining, Mayer
hematoxylin was used for 10 minutes, washing with water
after each step. To finish the process, dehydration in
alcohol and clearing in xylene were applied and the cov-
erslip mounted with Erv-mount.
Evaluation of immunohistochemical expression
The immunohistochemical analysis, verified by 4 ex-
aminers at different times was performed to identify pres-
ence or absence of immunohistochemical expression of
MMPs 1, 2, 7, 9, and 26 and their distribution pattern
(focal and diffuse). Semiquantitative analysis of immuno-
stained cells was performed by using parenchymal scores
(adapted from Nagel et al.15): 0 (10% of tumor cells
positive), 1 (11%-50% of tumor cells positive), and 2
(50% of tumor cells positive). The stroma was evaluated
for the presence or absence of immunoreactivity. After
obtaining the data, a descriptive analysis of the results was
performed.
RESULTS
MMPs 1, 2, 7, 9, and 26 were shown to be expressed in
variable amounts in both the parenchyma and the stroma
in all cases of CCOT with predominance of MMPs 1, 7,
and 9. The neoplastic cells exhibited cytoplasmic immu-
noreactivity. Ghost cells, sometimes calcified, also exhib-
ited immunopositivity for the MMPs studied.
Regarding the percentage of parenchymal cells im-
munostained, MMPs 1, 7, and 9 were scored as 2 in
100% of cases (Figs. 1-3). For MMP-2, there was a
predominance of score 0 (90%), whereas MMP-26 im-
ons
Incubation time Antigen retrieval
Overnight (18 h) Citrate pH 6.0 Pascal
60 min EDTA pH 8.0 Pascal
Overnight (18 h) Citrate pH 6.0 Pascal
Overnight (18 h) Pepsin pH 1.8, oven 37°C, 60 min
Overnight (18 h) Pepsin pH 1.8, oven 37°C, 60 minonditi
Dilution
1:100
1:50
1:20
1:250munostaining was varied (Table II; Figs. 4 and 5).
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for MMPs 1 (Fig. 6), 7, 9, and 26, whereas MMP 2
was expressed weakly in 80% of cases. It is noteworthy
that there was an even staining pattern of these MMPs
in the ghost cells that are part of the tumor parenchyma.
In analyzing the distribution pattern, a predominance
of diffuse pattern for MMPs 1 (100%), 7 (100%), 9
(90%), and 26 (100%) was observed, while for MMP-2
only 60% of cases exhibited this pattern.
DISCUSSION
Since the first description of calcifying odontogenic
cyst by Gorlin in 1962, different classifications have been
proposed in an attempt to define the nature of this pathol-
ogy. In the WHO classification of 1971, it was regarded to
be a cystic lesion. In 1992, WHO defined it as a neoplasm,
classified as an odontogenic tumor. According to this
Fig. 1. Immunoexpression of matrix metalloproteinase 1 in
calcifying cystic odontogenic tumor demonstrating cytoplas-
mic reactivity of neoplastic cells and ghost cells (400).
Fig. 2. Immunohistochemical staining for matrix metallopro-
teinase 7 in calcifying cystic odontogenic tumor (200).classification, all calcifying odontogenic cysts had a neo-plastic nature. However, other proposed classifications are
based on the dualistic concept of the existence of 2 sep-
arate entities, one cystic and the other neoplastic.16-19 In
2005, WHO classified the calcifying odontogenic cyst it
as a benign cystic neoplasm.1
The participation of metalloproteinases in the progres-
sion of odontogenic lesions has been shown in various
studies.20-28 These proteases have the ability to modulate
the ECM, modifying the structural and functional compo-
nents. Several MMPs are present in the formation of
dental tissues and may play an important role in the
biomineralization of dentin and enamel,29,30 but with low
expression under physiological conditions. On the other
hand, in pathologic processes, there is an overexpression
of these proteins, due to the imbalance between the activ-
ity and their inhibitors.7,31,32
Considering the calcifying cystic odontogenic tumor,
few studies have been conducted to evaluate the ex-
pression of metalloproteinases in these lesions. In the
present work, in general, MMPs were expressed in both
parenchymal and stromal cells but a immunoreactivity
for MMPs 1, 7, and 9 was observed, which reinforces
the idea of the involvement of stroma cells in the
Fig. 3. Matrix metalloproteinase 9 immunoexpression in cal-
cifying cystic odontogenic tumor (200).
Table II. Immunoreactive score for MMPs 1, 2, 7, 9,
and 26 in calcifying cystic odontogenic tumor, n (%)
MMP-1 MMP-2 MMP-7 MMP-9 MMP-26
Score 2 10 (100%) 0 (0%) 10 (100%) 10 (100%) 4 (40%)
Score 1 0 (0%) 1 (10%) 0 (0%) 0 (0%) 2 (20%)
Score 0 0 (0%) 9 (90%) 0 (0%) 0 (0%) 4 (40%)
Total 10 (100%) 10 (100%) 10 (100%) 10 (100%) 10 (100%)degradation of matrix components.
OOOOE
612 Ribeiro et al. November 2011There are several substrates of MMPs 1, 2, 7, 9,
and 26. MMP-1 degrades mainly collagens I, II, and
III. Gelatinases (MMPs 2 and 9) degrade mainly
denatured collagen (gelatin) and collagen type IV,
and the matrilysins MMP-7 and -26 digest various
components of the matrix, which include fibronectin
and collagen type IV.31
Score 2 was observed in 100% of cases for MMPs
1, 7, and 9. The positivity displayed by MMP-1
demonstrates the importance of this protease for the
degradation of ECM constituents, mainly collagen I,
promoting tumor growth and expansion. Similar re-
sults in relation to the expression of MMP-1 have
been demonstrated in other studies of odontogenic
tumors, such as ameloblastoma,22,24,27 odontogenic
tumor keratocystic,25 myxoma,33 and adenomatoid
Fig. 4. Immunoexpression of matrix metalloproteinase 2 in a
few tumor cells of calcifying cystic odontogenic tumor
(200).
Fig. 5. Matrix metalloproteinase 26 immunoexpression in
calcifying cystic odontogenic tumor (400).odontogenic tumor.27Amorim et al. (2004)34 analyzed the immunohisto-
chemical expression of tenascin, fibronectin, and collagen
IV in syndromic (SKOTs) and nonsyndromic (NSKOTs)
keratocystic odontogenic tumors and observed that there
were differences in the expression of these proteins be-
tween the lesions. Tenascin was present along the basal
membrane in all cases of SKOT, whereas in 5 cases of
NSKOT this protein was negative in certain areas. The
distribution of tenascin was focal on the SKOT wall and
diffuse in NSKOT. Fibronectin was detected with a dis-
continuous band in SKOT and discontinuous in NSKOT.
Collagen IV was not present in most cases of SKOT.
MMPs 2 and 9 are gelatinases, their main difference
being that MMP-2 can degrade collagen type I,35,36
both are involved in angiogenesis and in tumor
growth.28
Vincent et al. (2005)37 argue that these gelatinases
are important in the process of tumor invasion because
of the ability to degrade collagen type IV, the main
constituent of the basal membrane, which is the first
barrier to be breached in the process. Gong et al.
(2009)38 evaluated the immunohistochemical expres-
sion of MMP-9 in CCOT and concluded that the pos-
itivity of this enzyme in the stroma is associated with
the ability to promote tumor invasion. Our results dem-
onstrate focal immunostaining for MMP-2, whereas for
MMP-9 a score of 2 was observed in 100% of the cases
and a diffuse distribution pattern in parenchymal cells,
corroborating the studies of Ribeiro et al. (2009)27 that,
using the same pattern of immunostaining for these
MMPs in ameloblastomas and adenomatoid odonto-
genic tumor, found a prevalence of 0 scores for MMP-2
compared with marked expression of MMP-9. The
same was found by Kumamoto et al. (2003)22 and
Pinheiro et al. (2004)24 in studies with ameloblastomas
Fig. 6. Matrix metalloproteinase 1 immunopositivity in paren-
chymal and stroma cells of calcifying cystic odontogenic tumor
(400).and by Silveira et al. (2007)28 with odontogenic cysts.
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uent of the basement membrane (BM) and other ECM
components. We believe that the low expression of MMP is
due to the need to maintain a minimum of BM constituents,
which are crucial in the process of cell differentiation.
Silveira et al. (2007)28 evaluated the role of MMPs 1,
2, and 9 in radicular cysts (RCs), residual radicular
cysts (RRCs) and keratocystic odontogenic tumors
(KOTs). The expression of MMP-1 was predominantly
diffuse in the parenchyma of these lesions. Immunoex-
pression of MMP-2 ranged from focal (RC 60% and
KOT 100%) to diffuse (RRC 60%), and for MMP-9
immunoreactivity was predominantly focal, in contrast
to the expression found in CCOT, where in 90% of the
parenchyma immunostaining for MMP-2 was absent
whereas for MMP-9 the score 2 was predominant.
Considering the mesenchyme, there was a higher ex-
pression of these MMPs in KOT, as well as in CCOT in
our study, where there was 100% staining for MMPs 1
and 9 and absence of staining for MMP-2 was observed
in 80%, whereas that MMP was focal in 100% of KOT.
Compared with the cystic lesions, it appears that most
have not shown staining of MMPs, thus confirming the
presence of these MMPs in the mesenchyme participat-
ing in the active growth of the lesion.
The etiology of radicular cysts has been investigated as
correlated with MMPs. Soares et al. (2007)39 studied the
expression of MMPs 1, 2, and 9 in radicular cysts with and
without endodontic treatment: In the cystic epithelium a
strong expression of MMP-1 was noted regardless of the
type of treatment and of MMP-2 and MMP-9 in lesions
treated endodontically, but with no statistical difference.
Comparing these with the inflammatory markers, there
was no direct relationship between the marking of MMP-2
and inflammatory infiltrate, and this was also observed in
the work of de Paula-Silva et al. (2009).40 These data may
explain the weak or the absence of marking of MMP-2 in
CCOT, which is a neoplastic lesion, and in those cases
studied did not observe any reaction of this nature.
Among the various MMPs, the matrilysins, MMP-7
and MMP-26, are involved in diverse processes, such as
cell proliferation, apoptosis, invasion, and metastasis. Re-
searchers have demonstrated their expression in malignant
epithelial neoplasms41-43 and KOTs.25 However, until
now, no study has shown expression in calcifying cystic
odontogenic tumors.
MMP-7 is synthesized by epithelial cells and has the
ability to trigger a cascade of activity of MMPs and
degrade a variety of ECM substrates, including elastin,
laminin, collagen type IV, and others.44 MMP-7 also acts
on other substrates, such as tumor necrosis factor alpha,
myelin basic protein, Fas-ligand, E-cadherin, osteopontin,
and tissue growth factor. These substrates can modulate
cell behavior,45 which suggests that matrilysin may havea central role in the process of invasion and tumor metas-
tasis.46
MMP-26 is frequently expressed in both normal cells
and endometrium, placenta, and kidney, as well as in
epithelial neoplasms from various anatomic sites. It shows
proteolytic activity on various ECM components, includ-
ing fibronectin, collagen IV, gelatin, and fibrinogen.7,47
Cavalcante et al. (2008)25 evaluated the expression of
MMP-7 and MMP-26 in syndromic and nonsyndromic
keratocystic odontogenic tumors, and observed a strong
epithelial expression in cases associated with Gorlin syn-
drome compared to non-syndromic cases, which may
explain the more aggressive behavior of syndrome-asso-
ciated KOTs.
Studies were also performed on the immunohistochem-
ical expression of these matrilysins in ameloblastomas and
adenomatoid odontogenic tumors, trying to correlate with
distinct tumor biologic behavior of these pathologies.
However, Freitas et al. (2009)26 found no statistically
significant differences between the immunostaining of
both lesions, but there was a significant staining for
MMP-7 and MMP-26 in both the parenchyma and the
stroma, suggesting a role in the process of remodeling and
growth of these tumors.
In our results, the immunostaining of MMP-7 in the
parenchyma scores were 2 in 100% of cases, whereas
MMP-26 showed some variability. In the stroma, we
observed 100% staining of the matrilysins, thereby dem-
onstrating the involvement of these proteins in the inter-
action between epithelial cells and stroma in the process
of tumor growth and expansion.9,41 Besides degrading
ECM components, MMP-7 and MMP-26 are also able to
activate other metalloproteinases, such as MMP-9.
MMP-7 activates MMPs 2 and 9.48,49 MMPs 2 and 9
degrade collagen type IV, and these gelatinases are in-
volved in processes of tumor invasion and metastasis,50 as
referenced above.
The positivity evidenced by metalloproteinases 1, 7, 9, and
26 in stromal cells demonstrates that these enzymes are also
produced by fibroblasts, endothelial cells, inflammatory lym-
phocytes, plasma cells, and neutrophils, which are also in-
volved in the degradation of ECM. Similar results were
found in ameloblastomas,22,24 adenomatoid odontogenic tu-
mors (AOTs),26,27 and odontogenic cysts.28
Ghost cells are necessary prerequisites for the diagnosis
of CCOT, though not pathognomonic of these lesions.19
There is still much controversy about the nature of these
cells. Some researchers believe that they represent a nor-
mal or atypical keratinization,51 simple cellular degener-
ation, or a product of the abortive enamel matrix,52 or that
they derive from apoptotic processes of odontogenic cells
and originate from metaplastic transformation of odonto-
genic tumors.51,53 In all of the cases studied, the ghost
cells had the same staining pattern of MMPs in the pa-
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and 9, variability for MMP-26, and weak labeling for
MMP-2. Yoshida et al. (2001)54 analyzed the presence of
amelogenin protein in the ghost cells of CCOT, by im-
munohistochemistry study, and found that in 100% of
cases there was positive staining for this protein.
In a study with confocal microscopy of 15 CCOTs, for
analysis of the nature of these cells, an accumulation of
high-molecular-weight keratin was observed.51The re-
search of Kusama et al. (2005)55 verified the presence of
antibodies PA-HP1, PA-HP2, and MA-HP1 in 14 cases
of CCOT.
Takata et al. (2000)52 observed the presence of
MMP-20 in some ghost cells of CCOT, and in late stages
of odontogenesis within the immature enamel. Soares et
al. (2004),19 analyzing the presence of ECM proteins,
found strong immunohistochemical reactivity for fibronectin
followed in decreasing order by collagen I and tenascin C.
Watson et al. (1998)56 demonstrated that the matrix
produced by cells that are rapidly mineralizing contained
an amount of collagen I and fibronectin 3 times higher
than that secreted by clones of cells that were not miner-
alizing. Therefore, it is suggested that collagen I and
fibronectin are critical in the formation of calcified struc-
tures, being the predominant components in the matrix
produced by the mineralized cells. This evidence suggest
that the staining for these components of the ECM in these
cells is associated, probably, to the process of calcification
of ghost cells, a widely observed phenomenon in CCOT.
CONCLUSION
MMPs 1, 2, 7, 9, and 26 are expressed in parenchymal
and stromal cells of CCOTs, with the exception of
MMP-2, suggesting their contribution to tumor growth
and expansion. The presence of these metalloproteinases
in stromal cells reveals the active participation of these
cells, along with the parenchyma cells, in the degradation
of ECM constituents, contributing to the tumor growth
studied here. However, further studies investigating other
MMPs as well as using other techniques, such as zymog-
raphy and molecular biology, should be performed to
better understand the role and influence of these enzymes
in the behavior of the tumor studied here.
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